Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of bullous or non bullous impetigo. The patient has a total affected area comprised between 1-100 cm2 with surrounding erythema not extending more than 2 cm from the edge of any affected area. In case of multiple affected areas the total area will be the sum of each affected area and will not exceed 100 cm2. Additionally for patients \< 12 years the total area will not exceed a maximum of 2% of the body surface area.~* Total Skin Infection Rating Scale (SIRS) score of at least 8, including pus/exudate score of at least 1~Exclusion Criteria:~* Has a bacterial infection, which in the opinion of the investigator, could not be appropriately treated by a topical antibiotic.~* Has systemic signs and symptoms of infection (e.g. a fever; defined as an axillary temperature over 37.2 °C (99.0 °F)

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ozenoxacin 1% cream (Type: EXPERIMENTAL): 1% cream
- ozenoxacin placebo (Type: PLACEBO_COMPARATOR): cream
- retapamulin 1% ointment (Type: ACTIVE_COMPARATOR): 1% ointment

Based on this trial design, predict the completion outcome and termination type (if applicable).